Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?

Journal of Neuroinflammation

Volumn 11, Issue 1, 2014, Pages

  Loeffler, David A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Antibodies; A ; Complement activation; Cytokines; Immunotherapy; Intravenous immunoglobulin

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR ANTIBODY; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BAPINEUZUMAB; CRENEZUMAB; CYTOKINE ANTIBODY; FAS ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; PLACEBO; PROTEIN ANTIBODY; SIALIC ACID; SOLANEZUMAB; TAU PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; COGNITIVE DEFECT; COMPLEMENT ACTIVATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG PURIFICATION; DRUG SAFETY; DRUG TARGETING; HUMAN; NEUROPROTECTION; NONHUMAN; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; IMMUNOLOGY; TRENDS;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 84924912513     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/s12974-014-0198-z     Document Type: Review

References (159)

1. Association A's: Alzheimer's disease facts and figures. Alzheimers Dement 2014, 2014:e47-e92.
2. Alzheimers.net: Alzheimer's statistics. [http://www.alzheimers.net/resources/alzheimers-statistics/]
3. BrightFocus Foundation: Alzheimer's facts & statistics. [http://www.brightfocus.org/alzheimers/about/understanding/facts.html]
4. Hardy J, Allsop D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991, 12:383-388.
5. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, Rovira MB, Forette F, Orgogozo JM, AN1792(QS-21)-201 Study Team: Clinical effects of abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
6. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M, Bapineuzumab 201 Clinical Trial Investigators: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73:2061-2070.
7. Lilly: Lilly announces detailed results of the phase 3 solanezumab expedition studies following a presentation of the independent analyses by the Alzheimer's Disease Cooperative Study (ADCS). [https://investor.lilly.com/releasedetail.cfm?releaseid=711933]
8. Roche: Roche announces phase II clinical results of crenezumab in Alzheimer's disease. [http://www.roche.com/investors/ir_update/inv-update-2014-07-16.htm]
9. Lilly: Lilly voluntarily terminates phase II study for LY2886721, a beta secretase inhibitor, being investigated as a treatment for Alzheimer's disease. [https://investor.lilly.com/releasedetail.cfm?ReleaseID=771353]
10. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH: Tarenflurbil phase 3 study group: effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009, 302:2557-2564.
11. Lilly: Lilly halts development of semagacestat for Alzheimer's disease based on preliminary results of phase III clinical trials. In [https://investor.lilly.com/releasedetail.cfm?releaseid=499794]
12. Markesbery WR: Neuropathological criteria for the diagnosis of Alzheimer's disease. Neurobiol Aging 1997, 18:S13-S19.
13. Haroutunian V, Purohit DP, Perl DP, Marin D, Khan K, Lantz M, Davis KL, Mohs RC: Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol 1999, 56:713-718.
14. Giannakopoulos P, Herrmann FR, Bussière T, Bouras C, Kövari E, Perl DP, Morrison JH, Gold G, Hof PR: Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 2003, 60:1495-1500.
15. Bayry J, Kazatchkine MD, Kaveri SV: Shortage of human intravenous immunoglobulin - reasons and possible solutions. Nat Clin Pract Neurol 2007, 3:120-121.
16. Lutz HU, Binder CJ, Kaveri S: Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol 2009, 30:43-51.
17. Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ, Shoenfeld Y: Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation. Clin Exp Immunol 2009, 158(SUPPL 1):43-50.
18. Shoenfeld Y, Gershwin ME, Meroni PL: Autoantibodies (Second Edition). London: Elsevier; 2007.
19. Dodel R, Neff F, Noelker C, Pul R, Du Y, Bacher M, Oertel W: Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 2010, 70:513-528.
20. Loeffler DA, Klaver AC, Coffey MP: Aβ anti-idiotypic antibodies are present in intravenous immunoglobulin and are produced in mice following its administration. Autoimmunity 2014, Nov 13:1-5. [Epub ahead of print]. doi:10.3109/08916934.2014.983265.
21. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001, 345:747-755.
22. Sapir T, Blank M, Shoenfeld Y: Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann N Y Acad Sci 2005, 1051:743-778.
23. Avrameas S: Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 1991, 12:154-159.
24. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jäckel S, Wei X, Buerger K, Höft C, Hemmer B, Möller HJ, Farlow M, Oertel WH, Sommer N, Du Y: Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 2002, 52:253-256.
25. Balakrishnan K, Andrei-Selmer LC, Selmer T, Bacher M, Dodel R: Comparison of intravenous immunoglobulins for naturally occurring autoantibodies against amyloid-beta. J Alzheimers Dis 2010, 20:135-143.
26. Klaver AC, Finke JM, Digambaranath J, Balasubramaniam M, Loeffler DA: Antibody concentrations to Abeta1-42 monomer and soluble oligomers in untreated and antibody-antigen-dissociated intravenous immunoglobulin preparations. Int Immunopharmacol 2010, 10:115-119.
27. Dodel RC, Du Y, Depboylu C, Hampel H, Frölich L, Haag A, Hemmeter U, Paulsen S, Teipel SJ, Brettschneider S, Spottke A, Nölker C, Möller HJ, Wei X, Farlow M, Sommer N, Oertel WH: Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004, 75:1472-1474.
28. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, Younkin S, Younkin L, Schiff R, Weksler ME: 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009, 30:1728-1736.
29. Relkin N, Bettger L, Tsakanikas D, Ravdin L: Three-year follow-up on the IVIG for Alzheimer's phase II study. Alzheimers Dement 2012, 8:589.
30. Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F: Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013, 12:233-243.
31. Alzforum: Gammagard™ misses endpoints in phase 3 trial. [http://www.alzforum.org/news/research-news/gammagardtm-misses-endpoints-phase-3-trial]
32. ClinicalTrials.gov: A study to evaluate albumin and immunoglobulin in Alzheimer's disease (AMBAR). In [https://clinicaltrials.gov/show/NCT01561053]
33. ClinicalTrials.gov: Study of intravenous immunoglobulin in amnestic Mild Cognitive Impairment (MCI). [http://www.clinicaltrials.gov/ct2/show/NCT01300728]
34. Petersen RC, Negash S: Mild cognitive impairment: an overview. CNS Spectr 2008, 13:45-53.
35. Svetlicky N, Ortega-Hernandez OD, Mouthon L, Guillevin L, Thiesen HJ, Altman A, Kravitz MS, Blank M, Shoenfeld Y: The advantage of specific intravenous immunoglobulin (sIVIG) on regular IVIG: experience of the last decade. J Clin Immunol 2013, 33(SUPPL 1):S27-S32.
36. Shoenfeld Y, Rauova L, Gilburd B, Kvapil F, Goldberg I, Kopolovic J, Rovensky J, Blank M: Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 2002, 14:1303-1311.
37. Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E, Cervera R, Font J, Fridkin M, Thiesen HJ, Shoenfeld Y: The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol 2007, 19:857-865.
38. Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Wang N, Zhu KY, Brenner T, Laub O, Souroujon MC: A disease-specific fraction isolated from IVIG is essential for the immunosuppressive effect of IVIG in experimental autoimmune myasthenia gravis. J Neuroimmunol 2008, 194:89-96.
39. Mimouni D, Blank M, Payne AS, Anhalt GJ, Avivi C, Barshack I, David M, Shoenfeld Y: Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris. Clin Exp Immunol 2010, 162:543-549.
40. Makhoul B, Braun E, Herskovitz M, Ramadan R, Hadad S, Norberto K: Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis. Isr Med Assoc J 2009, 11:151-153.
41. Salama A, Kiefel V, Mueller-Eckhardt C: Effect of IgG anti-Rho(D) in adult patients with chronic autoimmune thrombocytopenia. Am J Hematol 1986, 22:241-250.
42. Knight EM, Gandy S: Immunomodulation and AD-down but not out. J Clin Immunol 2014, 34(SUPPL 1):S70-S73.
43. Kaneko Y, Nimmerjahn F, Ravetch JV: Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006, 313:670-673.
44. Relkin N: Clinical trials of intravenous immunoglobulin for Alzheimer's disease. J Clin Immunol 2014, 34(SUPPL 1):S74-S79.
45. Hack CE, Scheltens P: Intravenous immunoglobulins: a treatment for Alzheimer's disease? J Neurol Neurosurg Psychiatry 2004, 75:1374-1375.
46. Brannagan TH III: Intravenous gammaglobulin (IVIg) for treatment of CIDP and related immune-mediated neuropathies. Neurology 2002, 59:S33-S40.
47. Katz U, Achiron A, Sherer Y, Shoenfeld Y: Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007, 6:257-259.
48. Welles CC, Tambra S, Lafayette RA: Hemoglobinuria and acute kidney injury requiring hemodialysis following intravenous immunoglobulin infusion. Am J Kidney Dis 2010, 55:148-151.
49. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM: Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging 2003, 24:1063-1070.
50. Magga J, Puli L, Pihlaja R, Kanninen K, Neulamaa S, Malm T, Härtig W, Grosche J, Goldsteins G, Tanila H, Koistinaho J, Koistinaho M: Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation 2010, 7:90.
51. Puli L, Pomeshchik Y, Olas K, Malm T, Koistinaho J, Tanila H: Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer's disease. J Neuroinflammation 2012, 9:105.
52. Gong B, Pan Y, Zhao W, Knable L, Vempati P, Begum S, Ho L, Wang J, Yemul S, Barnum S, Bilski A, Gong BY, Pasinetti GM: IVIG immunotherapy protects against synaptic dysfunction in Alzheimer's disease through complement anaphylatoxin C5a-mediated AMPA-CREB-C/EBP signaling pathway. Mol Immunol 2013, 56:619-629.
53. Sudduth TL, Greenstein A, Wilcock DM: Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies. J Neurosci 2013, 33:9684-9692.
54. Dodel R, Balakrishnan K, Keyvani K, Deuster O, Neff F, Andrei-Selmer LC, Röskam S, Stüer C, Al-Abed Y, Noelker C, Balzer-Geldsetzer M, Oertel W, Du Y, Bacher M: Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci 2011, 31:5847-5854.
55. St-Amour I, Paré I, Tremblay C, Coulombe K, Bazin R, Calon F: IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Aβ pathology. J Neuroinflammation 2014, 11:54.
56. Counts S, Perez S, He B, Mufson E: IVIG reduces tau pathology and preserves neuroplastic gene expression in the 3xTg mouse model of Alzheimer's disease. Curr Alz Res 2014, 11:655-663.
57. Istrin G, Bosis E, Solomon B: Intravenous immunoglobulin enhances the clearance of fibrillar amyloid-beta peptide. J Neurosci Res 2006, 84:434-443.
58. Szabo P, Relkin N, Weksler ME: Natural human antibodies to amyloid beta peptide. Autoimmun Rev 2008, 7:415-420.
59. Du Y, Wei X, Dodel R, Sommer N, Hampel H, Gao F, Ma Z, Zhao L, Oertel WH, Farlow M: Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003, 126:1935-1939.
60. Smith LM, Coffey MP, Klaver AC, Loeffler DA: Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein. Int Immunopharmacol 2013, 16:424-428.
61. Szabo P, Mujalli DM, Rotondi ML, Sharma R, Weber A, Schwarz HP, Weksler ME, Relkin N: Measurement of anti-beta amyloid antibodies in human blood. J Neuroimmunol 2010, 227:167-174.
62. Welzel AT, Williams AD, McWilliams-Koeppen HP, Acero L, Weber A, Blinder V, Mably A, Bunk S, Hermann C, Farrell MA, Ehrlich HJ, Schwarz HP, Walsh DM, Solomon A, O'Nuallain B: Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide. PLoS One 2012, 7:e50317.
63. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ: An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci 2012, 32:9677-9689.
64. Cohen FE, Kelly JW: Therapeutic approaches to protein-misfolding diseases. Nature 2003, 426:905-909.
65. Rasool S, Martinez-Coria H, Wu JW, LaFerla F, Glabe CG: Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg-AD mice. J Neurochem 2013, 126:473-482.
66. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM: Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. a link between Abeta and tau pathology. J Biol Chem 2006, 281:1599-1604.
67. Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM, Gylys KH: Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes. Am J Pathol 2008, 172:1683-1692.
68. Wray S, Noble W: Linking amyloid and tau pathology in Alzheimer's disease: the role of membrane cholesterol in Abeta-mediated tau toxicity. J Neurosci 2009, 29:9665-9667.
69. Ma QL, Lim GP, Harris-White ME, Yang F, Ambegaokar SS, Ubeda OJ, Glabe CG, Teter B, Frautschy SA, Cole GM: Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro. J Neurosci Res 2006, 83:374-384.
70. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MW: A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A 1975, 72:1858-1862.
71. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, Reynolds CH, Ward MA, Anderton BH: Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 2007, 282:23645-23654.
72. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, Perl DP: Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer's disease. Arch Neurol 1995, 52:81-88.
73. Morsch R, Simon W, Coleman PD: Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 1999, 58:188-197.
74. Rankin CA, Sun Q, Gamblin TC: Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Mol Neurodegener 2007, 2:12.
75. Sigurdsson EM: Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis 2008, 15:157-168.
76. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M: Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 2011, 286:34457-34467.
77. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM: Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011, 118:658-667.
78. Wischik CM, Bentham P, Wischik DJ, Seng KM: Tau aggregation inhibitor (TAI) therapy with remberTM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimers and Dementia 2008, 4:T167.
79. ClinicalTrials.gov: Safety study of AADvac1, a Tau Peptide-KLH-conjugate active vaccine to treat Alzheimer's disease. [http://clinicaltrials.gov/show/NCT01850238]
80. Smith LM, Coffey MP, Loeffler DA: Specific binding of intravenous immunoglobulin products to tau peptide fragments. Int Immunopharmacol 2014, 21:279-282.
81. von Bergen M, Friedhoff P, Biernat J, Heberle J, Mandelkow EM, Mandelkow E: Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure. Proc Natl Acad Sci U S A 2000, 97:5129-5134.
82. Tokimasa M, Minoura K, Hiraoka S, Tomoo K, Sumida M, Taniguchi T, Ishida T: Importance of local structures of second and third repeat fragments of microtubule-binding domain for tau filament formation. FEBS Lett 2005, 579:3481-3486.
83. Taniguchi T, Sumida M, Hiraoka S, Tomoo K, Kakehi T, Minoura K, Sugiyama S, Inaka K, Ishida T, Saito N, Tanaka C: Effects of different anti-tau antibodies on tau fibrillogenesis: RTA-1 and RTA-2 counteract tau aggregation. FEBS Lett 2005, 579:1399-1404.
84. Rosenmann H, Meiner Z, Geylis V, Abramsky O, Steinitz M: Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects. Neurosci Lett 2006, 410:90-93.
85. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, et al: Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
86. Mrak RE, Griffin WS: Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging 2001, 22:903-908.
87. Lue LF, Brachova L, Civin WH, Rogers J: Inflammation, a beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J Neuropathol Exp Neurol 1996, 55:1083-1088.
88. Svenson M, Hansen MB, Bendtzen K: Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993, 92:2533-2539.
89. Ross C, Svenson M, Hansen MB, Vejlsgaard GL, Bendtzen K: High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest 1995, 95:1974-1978.
90. Toungouz M, Denys C, Dupont E: Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins. Transplantation 1996, 62:1292-1296.
91. Svenson M, Hansen MB, Ross C, Diamant M, Rieneck K, Nielsen H, Bendtzen K: Antibody to granulocyte-macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood 1998, 91:2054-2061.
92. Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO: Intravenous immunoglobulin and cytokines: focus on tumor necrosis factor family members BAFF and APRIL. Ann N Y Acad Sci 2007, 1110:426-432.
93. Dinarello CA: Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases. Curr Opin Immunol 1991, 3:941-948.
94. Ershler WB: Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc 1993, 41:176-181.
95. Zhan Y, Vega-Ramos J, Carrington EM, Villadangos JA, Lew AM, Xu Y: The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells. Eur J Immunol 2012, 42:2889-2900.
96. Tilg H, Peschel C: Interferon-alpha and its effects on the cytokine cascade: a pro- and anti-inflammatory cytokine. Leuk Lymphoma 1996, 23:55-60.
97. Mühl H, Pfeilschifter J: Anti-inflammatory properties of pro-inflammatory interferon-gamma. Int Immunopharmacol 2003, 3:1247-1255.
98. Cakebread JA, Xu Y, Grainge C, Kehagia V, Howarth PH, Holgate ST, Davies DE: Exogenous IFN-β has antiviral and anti-inflammatory properties in primary bronchial epithelial cells from asthmatic subjects exposed to rhinovirus. J Allergy Clin Immunol 2011, 127:1148-1154. e9.
99. Manczak M, Mao P, Nakamura K, Bebbington C, Park B, Reddy PH: Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. Hum Mol Genet 2009, 18:3876-3893.
100. Boyd TD, Bennett SP, Mori T, Governatori N, Runfeldt M, Norden M, Padmanabhan J, Neame P, Wefes I, Sanchez-Ramos J, Arendash GW, Potter H: GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice. J Alzheimers Dis 2010, 21:507-518.
101. Nimmerjahn F, Ravetch JV: The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 2007, 204:11-15.
102. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC, Ravetch JV: Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 2008, 320:373-376.
103. Käsermann F, Boerema DJ, Rüegsegger M, Hofmann A, Wymann S, Zuercher AW, Miescher S: Analysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionation. PLoS One 2012, 7:e37243.
104. Lories RJ, Casteels-Van Daele M, Ceuppens JL, Van Gool SW: Polyclonal immunoglobulins for intravenous use induce interleukin 10 release in vivo and in vitro. Ann Rheum Dis 2004, 63:747-748.
105. Craciun LI, DiGiambattista M, Laub R, Goldman M, Dupont E: Apoptosis: a target for potentiation of UV-induced IL-1Ra synthesis by IVIg. Immunol Lett 2007, 110:36-41.
106. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H: Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004, 323:630-635.
107. Basta M, Fries LF, Frank MM: High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991, 77:376-380.
108. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, Szebeni J, Alving CR, Carroll MC, Berkower I, Stojilkovic SS, Metcalfe DD: F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003, 9:431-438.
109. Lutz HU, Stammler P, Bianchi V, Trüeb RM, Hunziker T, Burger R, Jelezarova E, Späth PJ: Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004, 103:465-472.
110. Wegmüller E: Effect of intravenous immunoglobulin therapy on plasma complement. Transfus Sci 1998, 19:307-318.
111. Lutz HU, Stammler P, Jelezarova E, Nater M, Späth PJ: High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood 1996, 88:184-193.
112. Basta M, Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994, 94:1729-1735.
113. van Beek J, Elward K, Gasque P: Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci 2003, 992:56-71.
114. Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J: Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 1997, 18:415-421.
115. Arumugam TV, Tang SC, Lathia JD, Cheng A, Mughal MR, Chigurupati S, Magnus T, Chan SL, Jo DG, Ouyang X, Fairlie DP, Granger DN, Vortmeyer A, Basta M, Mattson MP: Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc Natl Acad Sci U S A 2007, 104:14104-14109.
116. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E: Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A 2002, 99:10837-10842.
117. Zhou J, Fonseca MI, Pisalyaput K, Tenner AJ: Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. J Neurochem 2008, 106:2080-2092.
118. Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA: Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 2008, 28:6333-6341.
119. Ager RR, Fonseca MI, Chu SH, Sanderson SD, Taylor SM, Woodruff TM, Tenner AJ: Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease. J Neurochem 2010, 113:389-401.
120. Fonseca MI, Chu SH, Berci AM, Benoit ME, Peters DG, Kimura Y, Tenner AJ: Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease. J Neuroinflammation 2011, 8:4.
121. Schwab C, Hosokawa M, McGeer PL: Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol 2004, 188:52-64.
122. Reichwald J, Danner S, Wiederhold KH, Staufenbiel M: Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation 2009, 6:35.
123. Gong B, Levine S, Barnum SR, Pasinetti GM: Role of complement systems in IVIG mediated attenuation of cognitive deterioration in Alzheimer's disease. Curr Alzheimer Res 2014, 11:637-644.
124. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: a review. Diabetologia 2001, 44:129-146.
125. Schmidt AM, Sahagan B, Nelson RB, Selmer J, Rothlein R, Bell JM: The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. Curr Opin Investig Drugs 2009, 10:672-680.
126. Hudson BI, Stickland MH, Grant PJ: Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups. Diabetes 1998, 47:1155-1157.
127. Berbaum K, Shanmugam K, Stuchbury G, Wiede F, Körner H, Münch G: Induction of novel cytokines and chemokines by advanced glycation endproducts determined with a cytometric bead array. Cytokine 2008, 41:198-203.
128. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B: RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003, 9:907-913.
129. Deane RJ: Is RAGE still a therapeutic target for Aleimer's disease? Future Med Chem 2012, 4:915-925.
130. Yan SS, Chen D, Yan S, Guo L, Du H, Chen JX: RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease. Front Biosci (Schol Ed) 2012, 4:240-250.
131. Weber A, Engelmaier A, Teschner W, Ehrlich HJ, Schwarz HP: Intravenous immunoglobulin (IVIg) Gammagard liquid contains anti-RAGE IgG and sLRP. Alzheimers Dement 2009, 5(SUPPL):416.
132. Counts SE, Ray B, Mufson EJ, Perez SE, He B, Lahiri DK: Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease. J Clin Immunol 2014, 34(SUPPL 1):S80-S85.
133. Widiapradja A, Vegh V, Lok KZ, Manzanero S, Thundyil J, Gelderblom M, Cheng YL, Pavlovski D, Tang SC, Jo DG, Magnus T, Chan SL, Sobey CG, Reutens D, Basta M, Mattson MP, Arumugam TV: Intravenous immunoglobulin protects neurons against amyloid beta-peptide toxicity and ischemic stroke by attenuating multiple cell death pathways. J Neurochem 2012, 122:321-332.
134. Yang ZH, Sun K, Suo WH, Yao LY, Fu Q, Cui YY, Fu GH, Chen HZ, Lu Y: N-stearoyltyrosine protects primary neurons from Aβ-induced apoptosis through modulating mitogen-activated protein kinase activity. Neuroscience 2010, 169:1840-1847.
135. Overmyer M, Kraszpulski M, Helisalmi S, Soininen H, Alafuzoff I: DNA fragmentation, gliosis and histological hallmarks of Alzheimer's disease. Acta Neuropathol 2000, 100:681-687.
136. Cribbs DH, Poon WW, Rissman RA, Blurton-Jones M: Caspase-mediated degeneration in Alzheimer's disease. Am J Pathol 2004, 165:353-355.
137. Kaufmann T, Strasser A, Jost PJ: Fas death receptor signalling: roles of Bid and XIAP. Cell Death Differ 2012, 19:42-50.
138. Komada Y, Sakurai M: Fas receptor (CD95)-mediated apoptosis in leukemic cells. Leuk Lymphoma 1997, 25:9-21.
139. Chodorge M, Züger S, Stirnimann C, Briand C, Jermutus L, Grütter MG, Minter RR: A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency. Cell Death Differ 2012, 19:1187-1195.
140. Uslu R, Borsellino N, Frost P, Gárban H, Ng CP, Mizutani Y, Belldegrun A, Bonavida B: Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis. Clin Cancer Res 1997, 3:963-972.
141. Nakatani K, Takeshita S, Tsujimoto H, Sekine I: Intravenous immunoglobulin (IVIG) preparations induce apoptosis in TNF-alpha-stimulated endothelial cells via a mitochondria-dependent pathway. Clin Exp Immunol 2002, 127:445-454.
142. Arredondo J, Chernyavsky AI, Karaouni A, Grando SA: Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus. Am J Pathol 2005, 167:1531-1544.
143. Reipert BM, Stellamor MT, Poell M, Ilas J, Sasgary M, Reipert S, Zimmermann K, Ehrlich H, Schwarz HP: Variation of anti-Fas antibodies in different lots of intravenous immunoglobulin. Vox Sang 2008, 94:334-341.
144. Altznauer F, von Gunten S, Späth P, Simon HU: Concurrent presence of agonistic and antagonistic anti-CD95 autoantibodies in intravenous Ig preparations. J Allergy Clin Immunol 2003, 112:1185-1190.
145. Dalakas MC: High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994, 44:223-226.
146. Mankarious S, Lee M, Fischer S, Pyun KH, Ochs HD, Oxelius VA, Wedgwood RJ: The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. J Lab Clin Med 1988, 112:634-640.
147. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O: Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006, 63:1459-1467.
148. Kügler S, Böcker K, Heusipp G, Greune L, Kim KS, Schmidt MA: Pertussis toxin transiently affects barrier integrity, organelle organization and transmigration of monocytes in a human brain microvascular endothelial cell barrier model. Cell Microbiol 2007, 9:619-632.
149. Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, Nousiopoulou E, Kassis I, Abramsky O, Karussis D, Rosenmann H: Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 2013, 248:451-456.
150. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H: Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010, 224:472-485.
151. Collins PW: Therapeutic challenges in acquired factor VIII deficiency. Hematol Am Soc Hematol Educ Program 2012, 2012:369-374.
152. Awad N, Cocchio C: Activated prothrombin complex concentrates for the reversal of anticoagulant-associated coagulopathy. Proc Natl Acad Sci U S A 2013, 38:696-701.
153. Cromwell C, Aledort LM: FEIBA: a prohemostatic agent. Semin Thromb Hemost 2012, 38:265-267.
154. Wiberg FC, Rasmussen SK, Frandsen TP, Rasmussen LK, Tengbjerg K, Coljee VW, Sharon J, Yang CY, Bregenholt S, Nielsen LS, Haurum JS, Tolstrup AB: Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng 2006, 94:396-405.
155. Rasmussen SK, Rasmussen LK, Weilguny D, Tolstrup AB: Manufacture of recombinant polyclonal antibodies. Biotechnol Lett 2007, 29:845-852.
156. Loeffler DA: Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation 2013, 10:70.
157. McFalls K: Plasma therapies: where are we now? [http://www.fffenterprises.com/news/articles/article-2011-05-03.html]
158. Shehata N, Palda V, Bowen T, Haddad E, Issekutz TB, Mazer B, Schellenberg R, Warrington R, Easton D, Anderson D, Hume H: The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev 2010, 24:S28-S50.
159. Mintz M: What if IVIG really worked for Alzheimer's? [http://drmintz.blogspot.com/2012/07/what-if-ivig-really-worked-for.html]